Prevention of Postoperative Pancreatic Fistula by Somatostatin

PHASE3CompletedINTERVENTIONAL
Enrollment

655

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

February 9, 2021

Study Completion Date

February 9, 2021

Conditions
Pancreatic Surgery
Interventions
DRUG

Somatostatin

Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days

DRUG

Octreotide

Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days

Trial Locations (2)

75013

La Pitié Salpêtrière Hospital, Paris

75014

Cochin Hospital, Paris

All Listed Sponsors
collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03000946 - Prevention of Postoperative Pancreatic Fistula by Somatostatin | Biotech Hunter | Biotech Hunter